<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845166</url>
  </required_header>
  <id_info>
    <org_study_id>XL092-001</org_study_id>
    <nct_id>NCT03845166</nct_id>
  </id_info>
  <brief_title>A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors</brief_title>
  <official_title>A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exelixis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exelixis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety,&#xD;
      tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers&#xD;
      of XL092 administered alone, in combination with atezolizumab, and in combination with&#xD;
      avelumab to subjects with advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>single-agent and combination therapy dose-escalation followed by cohort-expansion</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-Escalation Stage: MTD/recommended dose for XL092</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To determine the maximum tolerated dose (MTD) and/or recommended dose (RD) for further evaluation of XL092 when administered alone and in combination with immune checkpoint inhibitors (ICIs) to subjects with advanced solid tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort-Expansion Stage: Objective Response Rate (ORR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To evaluate preliminary efficacy of XL092 when administered alone and in combination with ICIs by estimating ORR as assessed by the Investigator per RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort-Expansion Stage: Progression-Free Survival (PFS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To evaluate preliminary efficacy of single-agent XL092 and XL092 in combination with ICIs for specific cohorts by estimating the percentage of subjects with PFS at 6 months (PFS rate) per RECIST 1.1 as assessed by the Investigator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Nonserious Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>To evaluate the safety of XL092 when administered alone and in combination with ICIs through the evaluation of incidence and severity of nonserious AEs and SAEs, including immune-related adverse events (irAEs), and adverse events of special interest (AESIs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-Escalation Stage: Time to Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To evaluate the Tmax of XL092 alone and in combination with ICI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-Escalation Stage: Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To evaluate the Cmax of XL092 alone and in combination with ICI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-Escalation Stage: Area Under the Plasma Concentration-Time Curve Over the Last 24-hour Dosing Interval (AUC 0-24)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To evaluate the AUC 0-24 of XL092 alone and in combination with ICI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-Escalation Stage: Terminal Half-Life</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To evaluate the terminal half-life of XL092 alone and in combination with ICI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-Escalation Stage: Apparent Clearance (CL/F)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>To evaluate the CL/F of XL092 alone and in combination with ICI</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Neoplasm Malignant</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Hormone Receptor Positive Breast Carcinoma</condition>
  <condition>Metastatic Castration-resistant Prostate Cancer</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>XL092 Single-Agent Dose-Escalation Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will accrue in cohorts of 3-6 subjects in a standard &quot;3 plus 3&quot; design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XL092 Single-Agent Expansion Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The MTD or recommended dose from the dose-escalation stage may be further explored in clear cell renal cell carcinoma (ccRCC), non-clear cell renal cell carcinoma (nccRCC), hormone receptor-positive breast cancer (HR+ BC), and metastatic castration-resistant prostate cancer (mCRPC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XL092 + Atezolizumab Dose-Escalation Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will accrue in cohorts of 2-6 subjects in a &quot;rolling 6&quot; design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XL092 + Atezolizumab Expansion Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The MTD or recommended dose from the dose-escalation stage may be further explored in non-clear cell renal cell carcinoma (nccRCC), hormone receptor-positive breast cancer (HR+ BC), metastatic castration-resistant prostate cancer (mCRPC), and colorectal cancer (CRC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XL092 + Avelumab Dose-Escalation Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will accrue in cohorts of 2-6 subjects in a &quot;rolling 6&quot; design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XL092 + Avelumab Expansion Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The MTD or recommended dose from the dose-escalation stage may be further explored in advanced urothelial carcinoma (UC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XL092</intervention_name>
    <description>oral doses of XL092</description>
    <arm_group_label>XL092 + Atezolizumab Dose-Escalation Cohorts</arm_group_label>
    <arm_group_label>XL092 + Atezolizumab Expansion Cohorts</arm_group_label>
    <arm_group_label>XL092 + Avelumab Dose-Escalation Cohorts</arm_group_label>
    <arm_group_label>XL092 + Avelumab Expansion Cohorts</arm_group_label>
    <arm_group_label>XL092 Single-Agent Dose-Escalation Cohorts</arm_group_label>
    <arm_group_label>XL092 Single-Agent Expansion Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once every 3 weeks (q3w)</description>
    <arm_group_label>XL092 + Atezolizumab Dose-Escalation Cohorts</arm_group_label>
    <arm_group_label>XL092 + Atezolizumab Expansion Cohorts</arm_group_label>
    <other_name>Tecentriq®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Supplied as 200 mg/10 mL vials; administered as an 800 mg IV infusion once every 2 weeks (q2w)</description>
    <arm_group_label>XL092 + Avelumab Dose-Escalation Cohorts</arm_group_label>
    <arm_group_label>XL092 + Avelumab Expansion Cohorts</arm_group_label>
    <other_name>Bavencio®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cytologically or histologically confirmed solid tumor that is inoperable locally&#xD;
             advanced, metastatic, or recurrent.&#xD;
&#xD;
          -  Dose-escalation (single-agent and combination therapy): Subjects with a solid tumor&#xD;
             that is unresectable or metastatic and for which life-prolonging therapies do not&#xD;
             exist or available therapies are intolerable or no longer effective.&#xD;
&#xD;
          -  Expansion Cohort A (ccRCC): Subjects with previously treated advanced RCC with clear&#xD;
             cell histology (including those with a sarcomatoid component) who have&#xD;
             radiographically progressed following treatment with at least one prior systemic&#xD;
             anticancer regimen for inoperable locally advanced or metastatic disease.&#xD;
&#xD;
          -  Expansion Cohorts B and E (nccRCC): Subjects with previously treated advanced RCC with&#xD;
             non-clear cell histology who have radiographically progressed following treatment with&#xD;
             at least one prior systemic anticancer regimen for inoperable locally advanced or&#xD;
             metastatic disease.&#xD;
&#xD;
          -  Expansion Cohorts C and F (HR+ BC): Subjects with breast cancer that is hormone&#xD;
             receptor positive (ER+ and/or PR+) and negative for human epidermal growth factor&#xD;
             receptor 2 (HER-2) and who have radiographically progressed during or following&#xD;
             treatment with at least one prior systemic anticancer regimen for inoperable locally&#xD;
             advanced or metastatic disease.&#xD;
&#xD;
          -  Expansion Cohorts D and G (mCRPC): Subjects with metastatic CRPC (adenocarcinoma of&#xD;
             the prostate). Neuroendocrine differentiation and other features permitted if&#xD;
             adenocarcinoma is the primary histology.&#xD;
&#xD;
          -  Expansion Cohort H (CRC): Subjects with histologically confirmed unresectable, locally&#xD;
             advanced, or metastatic adenocarcinoma of the colon or rectum who received prior&#xD;
             fluoropyrimidine-containing chemotherapy with oxaliplatin or irinotecan.&#xD;
&#xD;
          -  Expansion Cohort I (UC, Maintenance Therapy): Subjects with histologically confirmed,&#xD;
             unresectable, locally advanced or metastatic transitional cell carcinoma of the&#xD;
             urothelium (including the renal pelvis, ureter, urinary bladder, or urethra) who&#xD;
             received first-line chemotherapy of gemcitabine + cisplatin and/or gemcitabine +&#xD;
             carboplatin.&#xD;
&#xD;
          -  Expansion Cohort J (UC, ICI-refractory): Subjects with histologically confirmed,&#xD;
             unresectable, locally advanced or metastatic transitional cell carcinoma of the&#xD;
             urothelium (including the renal pelvis, ureter, urinary bladder, or urethra) who&#xD;
             progressed on or after PD-1/PD-L1 targeting ICI therapy.&#xD;
&#xD;
          -  Expansion Cohort K (UC, platinum-refractory): Subjects with histologically confirmed,&#xD;
             unresectable, locally advanced or metastatic transitional cell carcinoma of the&#xD;
             urothelium (including the renal pelvis, ureter, urinary bladder, or urethra) who&#xD;
             progressed on or after first-line platinum-based combination therapy.&#xD;
&#xD;
          -  Expansion Cohorts: Subjects must have measurable disease per RECIST 1.1, with&#xD;
             exception of Cohort I (UC, Maintenance Therapy).&#xD;
&#xD;
          -  Tumor tissue material:&#xD;
&#xD;
               -  Subjects in the non-biomarker cohort provide archival, if available, or fresh&#xD;
                  tumor tissue if it can be safely obtained.&#xD;
&#xD;
               -  Subjects in the Biomarker Cohorts provide fresh tumor and skin biopsies.&#xD;
&#xD;
          -  Recovery to baseline or ≤ Grade 1 severity (CTCAE v5) from adverse events (AEs),&#xD;
             including immune-related adverse events (irAEs), related to any prior treatments,&#xD;
             unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.&#xD;
&#xD;
          -  Adequate organ and marrow function.&#xD;
&#xD;
          -  Sexually active fertile subjects and their partners must agree to use medically&#xD;
             accepted methods of contraception.&#xD;
&#xD;
          -  Female subjects of childbearing potential must not be pregnant at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with XL092 (all cohorts), prior treatment with PD-L1/PD-1 targeting&#xD;
             immune checkpoint inhibitor (Cohorts E, F, G, H, I, and K only) or prior avelumab&#xD;
             (Cohort J only).&#xD;
&#xD;
          -  Receipt of any type of small molecule kinase inhibitor within 2 weeks before first&#xD;
             dose of study treatment.&#xD;
&#xD;
          -  Receipt of any type of anticancer antibody, systemic chemotherapy, or hormonal&#xD;
             anticancer therapy within 4 weeks before first dose of study treatment.&#xD;
&#xD;
          -  Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy&#xD;
             within 4 weeks before first dose of study treatment. Subjects with clinically relevant&#xD;
             ongoing complications from prior radiation therapy are not eligible.&#xD;
&#xD;
          -  Known brain metastases or cranial epidural disease unless adequately treated with&#xD;
             radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks&#xD;
             before first dose of study treatment.&#xD;
&#xD;
          -  Uncontrolled, significant intercurrent or recent illness.&#xD;
&#xD;
          -  Concomitant use of certain medications.&#xD;
&#xD;
          -  Corrected QT interval calculated by the Fridericia formula (QTcF) &gt; 460 ms within 10&#xD;
             days per electrocardiogram (ECG) before first dose of study treatment.&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Diagnosis of another malignancy within 2 years before first dose of study treatment,&#xD;
             except for superficial skin cancers, or localized, low grade tumors deemed cured and&#xD;
             not treated with systemic therapy.&#xD;
&#xD;
        Additional Exclusion Criteria for XL092 + Atezolizumab Combination Therapy Cohorts ONLY:&#xD;
&#xD;
          -  Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other&#xD;
             form of immunosuppressive therapy within 2 weeks prior to first dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  Administration of a live, attenuated vaccine within 30 days before first dose of study&#xD;
             treatment.&#xD;
&#xD;
        Additional Exclusion Criteria for XL092 + Avelumab Combination Therapy Cohorts ONLY:&#xD;
&#xD;
          -  Active autoimmune disease that might deteriorate when receiving an immunostimulatory&#xD;
             agent.&#xD;
&#xD;
          -  Administration of a live, attenuated vaccine within 30 days before first dose of study&#xD;
             treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Exelixis Clinical Trials</last_name>
    <phone>1-888-EXELIXIS (888-393-5494)</phone>
    <email>druginfo@exelixis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Backup or International</last_name>
    <phone>650-837-7400</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Exelixis Clinical Site #6</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Exelixis Clinical Site #7</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Exelixis Clinical Site #4</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Exelixis Clinical Site #2</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Exelixis Clinical Site #3</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Exelixis Clinical Site #1</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Exelixis Clinical Site #5</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

